# A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

> **NCT05859074** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 56 (estimated)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma
- SCC - Squamous Cell Carcinoma
- Basal Cell Carcinoma
- BCC
- BCC - Basal Cell Carcinoma
- Melanoma
- Merkel Cell Carcinoma
- Sebaceous Carcinoma
- Extramammary Paget Disease
- Kaposi Sarcoma
- Head and Neck Squamous Cell Carcinoma
- HNSCC
- Adnexal Carcinoma
- Angiosarcoma
- Cutaneous Neoplasm
- Advanced Cancer
- Metastatic Cancer
- Refractory Cancer
- Solid Tumor

## Interventions

- **BIOLOGICAL:** MQ719
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05859074
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-04
- **Primary completion:** 2028-05-04
- **Final completion:** 2028-05-04
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05859074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05859074, "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05859074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*